{
    "clinical_study": {
        "@rank": "18453", 
        "arm_group": [
            {
                "arm_group_label": "Prebiotic first", 
                "arm_group_type": "Active Comparator", 
                "description": "This group will receive bovine milk oligosaccharides, administered orally twice per day for a daily total of 0.3 g per pound of body weight."
            }, 
            {
                "arm_group_label": "Synbiotic first", 
                "arm_group_type": "Active Comparator", 
                "description": "This group will receive Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the tolerability of dietary supplements and if\n      these supplements can promote a healthy bacterial environment in the intestines of children\n      with autism spectrum disorders and gastrointestinal complaints."
        }, 
        "brief_title": "Effect of Milk Oligosaccharides and Bifidobacteria on the Intestinal Microflora of Children With Autism", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Autism", 
        "condition_browse": {
            "mesh_term": "Autistic Disorder"
        }, 
        "detailed_description": {
            "textblock": "This study investigates the feasibility, tolerability, and effects of a dietary supplement\n      on the intestinal flora of children with autism spectrum disorders. This study is divided\n      into two parts, each five weeks long, with a two week break in between. During one part of\n      the study, a prebiotic (milk oligosaccharides from bovine colostrum) will be given. During\n      the other part of the study, the synbiotic composed of the prebiotic and probiotic\n      (bifidobacterium infantis) will be given.  Stool will be analyzed at the end of each study\n      arm to determine content of bifidobacteria."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Autism\n\n          -  Diarrhea and/or constipation\n\n        Exclusion Criteria:\n\n          -  Milk protein or other documented food allergy\n\n          -  Lactose intolerance\n\n          -  Compromised Immunity\n\n          -  GI conditions (inflammatory bowel disease, celiac disease, short gut, etc.)\n\n          -  Systemic steroid, antifungal, or antibiotic use within a month of starting the study\n\n          -  Failure to thrive\n\n          -  Medically prescribed diets or supplements (including probiotic use within the past\n             month).\n\n          -  Vegetarian or dairy restricted diet\n\n          -  Other medical conditions (seizures, genetic disorders, liver/pancreatic disease,\n             cystic fibrosis, etc.)\n\n          -  Medications that interfere or alter intestinal motility or microbiota composition.\n\n          -  Full scale intelligence quotient (IQ) <40"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02086110", 
            "org_study_id": "450072"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Prebiotic first", 
                    "Synbiotic first"
                ], 
                "intervention_name": "Synbiotic", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "Bifidobacterium infantis SC268", 
                    "bovine colostrum, bovine oligosaccharides"
                ]
            }, 
            {
                "arm_group_label": [
                    "Prebiotic first", 
                    "Synbiotic first"
                ], 
                "intervention_name": "Prebiotic", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "bovine colostrum, bovine oligosaccharides"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "probiotic", 
            "prebiotic", 
            "autism", 
            "oligosaccharides", 
            "Bifidobacterium infantis"
        ], 
        "lastchanged_date": "March 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sacramento", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "95817"
                }, 
                "name": "UC Davis MIND Institute"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Study Examining Microbiota Composition in Children With Autism and Gastrointestinal Symptoms After Use of Bifidobacterium Infantis and Milk Oligosaccharides", 
        "overall_contact": {
            "email": "jonathan.polussa@ucdmc.ucdavis.edu", 
            "last_name": "Jonathan Polussa, BS", 
            "phone": "916.703.0477"
        }, 
        "overall_official": {
            "affiliation": "UC Davis MIND Institute", 
            "last_name": "Kathleen Angkustsiri, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The stool microbiome composition will be analyzed through next generation sequencing and quantitative polymerase chain reaction. Both the overall bacterial composition will be analyzed as well as specific Bifidobacteria species present.", 
            "measure": "Stool Microbiota Composition", 
            "safety_issue": "No", 
            "time_frame": "Five weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02086110"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, Davis", 
            "investigator_full_name": "Kathleen Angkustsiri, MD", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Luminex technology will be used to determine a serum immune profile of each participants in response to the study supplement. This profile will include pro-inflammatory cytokines (IFNg, IL-1, IL-6, IL-13 and TNFa) and anti-inflammatory cytokines (IL-10 and TGFb1).", 
                "measure": "Serum Immune Profile", 
                "safety_issue": "No", 
                "time_frame": "5 weeks"
            }, 
            {
                "description": "An ELISA (enzyme-linked immunosorbent assay) will be used to determine participants' immunoglobulin (Ig) levels (IgA, IgG and IgM) in response to the study supplement.", 
                "measure": "Serum Immunoglobin Level", 
                "safety_issue": "No", 
                "time_frame": "Five weeks"
            }
        ], 
        "source": "University of California, Davis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of California, Davis", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}